- Prostate Cancer -
- Phase 2
An investigational oral PROTAC androgen receptor (AR) degrader.
Arvinas is dedicated to advancing cancer care by developing PROTAC protein degraders for a variety of cancers.
Learn about our clinical stage oncology development programs by selecting a compound below.
Click here to explore our full pipeline of PROTAC protein degraders.
Oncology Development Programs
All Arvinas programs, with the exception of vepdegestrant are wholly owned. The agents listed below are currently under investigation. Their safety and effectiveness have not been established. Future regulatory approval or commercial availability of these pipeline products is not guaranteed.
An investigational oral PROTAC androgen receptor (AR) degrader.
An investigational oral PROTAC estrogen receptor (ER) degrader.
Vepdegestrant is being co-developed with Pfizer.
An investigational oral PROTAC androgen receptor (AR) degrader.
ARV-766 is out-licensed to Novartis.
An investigational oral PROTAC B-cell lymphoma 6 (BCL6) degrader.
You are now leaving arvinasoncologymedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.
This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.
By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).
If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.